BECTON DICKINSON & CO
BDXAPI behind this page
BDX Q3 2025 request
Playground key active
/api/financials?ticker=BDX&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 5,509 | 4,990 | +10.4% |
Show Business Segments breakouts |
|||
| Interventional · Non Us | 241 | 225 | +7.1% |
| Interventional · Non Us | 101 | 93 | +8.6% |
| Interventional · Non Us | 88 | 78 | +12.8% |
| Interventional · Non Us | 430 | 396 | +8.6% |
| Interventional · Operating Segments | 1,328 | 1,240 | +7.1% |
| Interventional · Peripheral Intervention | 512 | 488 | +4.9% |
| Interventional · Surgery | 395 | 376 | +5.1% |
| Interventional · Urology and Critical Care | 422 | 375 | +12.5% |
| Interventional · US | 271 | 263 | +3.0% |
| Interventional · US | 294 | 283 | +3.9% |
| Interventional · US | 334 | 297 | +12.5% |
| Interventional · US | 898 | 844 | +6.4% |
| Life Sciences · Biosciences | 358 | 363 | -1.4% |
| Life Sciences · Diagnostic Solutions | 425 | 429 | -0.9% |
| Life Sciences · Non Us | 213 | 222 | -4.1% |
| Life Sciences · Non Us | 271 | 263 | +3.0% |
| Life Sciences · Non Us | 230 | 228 | +0.9% |
| Life Sciences · Non Us | 714 | 714 | 0.0% |
| Life Sciences · Operating Segments | 1,254 | 1,260 | -0.5% |
| Life Sciences · Specimen Management | 470 | 467 | +0.6% |
| Life Sciences · US | 145 | 141 | +2.8% |
| Life Sciences · US | 154 | 167 | -7.8% |
| Life Sciences · US | 240 | 239 | +0.4% |
| Life Sciences · US | 539 | 546 | -1.3% |
| Medical · Advanced Patient Monitoring | 278 | — | — |
| Medical · Medication Delivery Solutions | 1,132 | 1,123 | +0.8% |
| Medical · Medication Management Solutions | 888 | 840 | +5.7% |
| Medical · Non Us | 452 | 453 | -0.2% |
| Medical · Non Us | 179 | 160 | +11.9% |
| Medical · Non Us | 451 | 437 | +3.2% |
| Medical · Non Us | 1,184 | 1,050 | +12.8% |
| Medical · Non Us | 102 | — | — |
| Medical · Operating Segments | 2,927 | 2,558 | +14.4% |
| Medical · Pharmaceutical Systems | 629 | 594 | +5.9% |
| Medical · US | 680 | 670 | +1.5% |
| Medical · US | 709 | 680 | +4.3% |
| Medical · US | 178 | 158 | +12.7% |
| Medical · US | 1,743 | 1,508 | +15.6% |
| Medical · US | 176 | — | — |
Show Geography breakouts |
|||
| Non Us | 2,328 | 2,098 | +11.0% |
| US | 3,181 | 2,891 | +10.0% |
| Cost of Revenue | 2,875 | 2,683 | +7.2% |
| Selling, General & Administrative | 1,320 | 1,196 | +10.4% |
| Research & Development | 297 | 299 | -0.7% |
| Integration Restructuring And Transaction Expense | 97 | 112 | -13.4% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 97 | 112 | -13.4% |
| Other Operating Income Expense Net | 38 | 98 | -61.2% |
| Total Costs & Expenses | 4,627 | 4,388 | +5.4% |
| Operating Income | 882 | 602 | +46.5% |
| Interest Expense | 152 | 137 | +10.9% |
| Interest Income | 5 | 48 | -89.6% |
| Other Non-Operating Income (Expense) | -33 | -13 | -153.8% |
| Income Before Taxes | 703 | 500 | +40.6% |
| Income Tax Expense (Benefit) | 129 | 13 | +892.3% |
| Net Income | 574 | 487 | +17.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 574 | 487 | +17.9% |
| EPS (Basic) | 2 | 1.68 | +19.0% |
| EPS (Diluted) | 2 | 1.68 | +19.0% |
| Common Stock Dividends Per Share Declared | 1.04 | 0.95 | +9.5% |
| Comprehensive Income | 477 | 443 | +7.7% |
| Wtd Avg Shares (Basic) | 287,170 | 289,562 | -0.8% |
| Wtd Avg Shares (Diluted) | 287,223 | 290,253 | -1.0% |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Interventional · Operating Segments | 376 | 365 | +3.0% |
| Life Sciences · Operating Segments | 391 | 387 | +1.0% |
| Medical · Operating Segments | 880 | 753 | +16.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -701 | -804 | +12.8% |
| Operating Segments | 1,647 | 1,505 | +9.4% |
| Interest Income Expense Net (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -147 | -89 | -65.2% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 735 | 4,459 | -83.5% |
| Restricted Cash And Investments Current | 62 | 28 | +121.4% |
| Other Short Term Investments | 22 | 851 | -97.4% |
| Accounts Receivable | 2,943 | 2,596 | +13.4% |
| Inventory Raw Materials Net Of Reserves | 920 | 763 | +20.6% |
| Inventory Work In Process Net Of Reserves | 512 | 406 | +26.1% |
| Inventory Finished Goods Net Of Reserves | 2,518 | 2,087 | +20.7% |
| Inventory | 3,949 | 3,255 | +21.3% |
| Other Assets Current | 1,285 | 1,018 | +26.2% |
| Total Current Assets | 8,997 | 12,207 | -26.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 6,818 | 6,518 | +4.6% |
| Goodwill | 26,597 | — | — |
Show Business Segments breakouts |
|||
| Interventional | 12,756 | — | — |
| Life Sciences | 913 | — | — |
| Medical | 12,928 | — | — |
Show Business Acquisition breakouts |
|||
| Advanced Patient Monitoring | 1.9 | — | — |
| Other Non-Current Assets | 2,702 | 2,401 | +12.5% |
| Total Assets | 54,902 | 55,582 | -1.2% |
| Intangible Assets | 9,771 | 9,864 | -0.9% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 2,334 | 2,076 | +12.4% |
| Developed Technology Rights | 6,928 | 7,275 | -4.8% |
| Intellectual Property | 510 | 513 | -0.6% |
| Other Assets | |||
| Property Plant And Equipment Gross | 14,854 | 13,922 | +6.7% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 8,036 | 7,404 | +8.5% |
| Core And Developed Technology Net | 6,928 | 7,275 | -4.8% |
| Finite Lived Customer Relationships Net | 2,334 | 2,076 | +12.4% |
| Other Intangible Assets Net | 526 | 559 | -5.9% |
| Current Liabilities | |||
| Debt Current | 1,810 | 1,192 | +51.8% |
| Accounts Payable And Accrued Liabilities Current | 6,350 | 5,413 | +17.3% |
| Total Current Liabilities | 8,160 | 6,605 | +23.5% |
| Non-Current Liabilities | |||
| Long-Term Debt | 17,531 | 18,131 | -3.3% |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 908 | 907 | +0.1% |
| Other Non-Current Liabilities | 2,831 | 4,071 | -30.5% |
| Stockholders' Equity | |||
| Common Stock | 371 | 371 | 0.0% |
| Additional Paid In Capital Common Stock | 20,024 | 19,847 | +0.9% |
| Retained Earnings | 16,426 | 16,015 | +2.6% |
| Common Stock Shares Held In Employee Trust1 | 26 | 22 | +18.2% |
| Treasury Stock Value | -9,561 | -8,807 | -8.6% |
| Accumulated Other Comprehensive Income | -1,813 | — | — |
| Total Stockholders' Equity | 25,472 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -533 | -536 | +0.6% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 80 | 90 | -11.1% |
| Accumulated Other Comprehensive Income | -1,813 | -1,579 | -14.8% |
| Accumulated Translation Adjustment | -1,360 | -1,132 | -20.1% |
| Additional Paid In Capital | 20,024 | 19,847 | +0.9% |
| Common Stock | 371 | 371 | 0.0% |
| Deferred Compensation Share Based Payments | 26 | 22 | +18.2% |
| Retained Earnings | 16,426 | 16,015 | +2.6% |
| Treasury Stock Common | -9,561 | -8,807 | -8.6% |
| Total Liabilities & Equity | 54,902 | 55,582 | -1.2% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 1,833 | 1,700 | +7.8% |
| Stock-Based Compensation | 203 | 196 | +3.6% |
| Deferred Income Taxes And Tax Credits | -255 | -299 | +14.7% |
| Increase Decrease In Operating Capital | -1,050 | -197 | -433.0% |
| Increase Decreasein Pension Benefit Obligation | 23 | -85 | +127.1% |
| Other Operating Activities Cash Flow Statement | 137 | 45 | +204.4% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 2,076 | 2,666 | -22.1% |
| Investing Activities | |||
| Capital Expenditures | -408 | -429 | +4.9% |
| Payments For Proceeds From Investments | 408 | -830 | +149.2% |
| Other Investing Activities | -324 | -318 | -1.9% |
| Net Cash from Investing | -324 | -1,577 | +79.5% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt | 133 | — | — |
| Repayments Of Long Term Debt | -1,209 | -1,142 | -5.9% |
| Share Repurchases | -750 | -500 | -50.0% |
| Payments Of Dividends | -899 | -825 | -9.0% |
| Proceeds From Payments For Other Financing Activities | -83 | -88 | +5.7% |
| Net Cash from Financing | -2,808 | 1,963 | -243.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -2 | — | — |
| Net Change in Cash | -1,058 | 3,006 | -135.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 798 | 4,487 | -82.2% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.